{
  "template_id": "Jejunum_Ileum.NET_2.0.0.0.REL_CAPCP",
  "organ": "JEJUNUM AND ILEUM NEUROENDOCRINE TUMOR",
  "protocol_posting_date": "December 2023",
  "standards": [
    "AJCC-UICC 9"
  ],
  "sections": [
    {
      "section_id": "specimen",
      "section_name": "SPECIMEN",
      "fields": [
        {
          "field_id": "procedure",
          "label": "Procedure",
          "required": true,
          "type": "single_select",
          "options": [
            {
              "value": "segmental_resection_small_intestine",
              "label": "Segmental resection, small intestine"
            },
            {
              "value": "ileocolic_resection",
              "label": "Ileocolic resection"
            },
            {
              "value": "other",
              "label": "Other (specify): _________________",
              "has_free_text": true
            },
            {
              "value": "not_specified",
              "label": "Not specified"
            }
          ]
        }
      ]
    },
    {
      "section_id": "tumor",
      "section_name": "TUMOR",
      "fields": [
        {
          "field_id": "tumor_site",
          "label": "Tumor Site",
          "required": true,
          "type": "single_select",
          "options": [
            {
              "value": "jejunum",
              "label": "Jejunum: _________________",
              "has_free_text": true
            },
            {
              "value": "ileum",
              "label": "Ileum: _________________",
              "has_free_text": true
            },
            {
              "value": "small_intestine_not_otherwise_specified",
              "label": "Small intestine, not otherwise specified: _________________",
              "has_free_text": true
            },
            {
              "value": "other",
              "label": "Other (specify): _________________",
              "has_free_text": true
            }
          ],
          "notes": [
            "A",
            "B"
          ]
        },
        {
          "field_id": "histologic_type_and_grade",
          "label": "Histologic Type and Grade#",
          "required": true,
          "type": "single_select",
          "options": [
            {
              "value": "g1_well_differentiated_neuroendocrine_tumor",
              "label": "G1, well-differentiated neuroendocrine tumor"
            },
            {
              "value": "g2_well_differentiated_neuroendocrine_tumor",
              "label": "G2, well-differentiated neuroendocrine tumor"
            },
            {
              "value": "g3_well_differentiated_neuroendocrine_tumor",
              "label": "G3, well-differentiated neuroendocrine tumor"
            },
            {
              "value": "gx_grade_cannot_be_assessed",
              "label": "GX, grade cannot be assessed"
            },
            {
              "value": "other",
              "label": "Other (specify): _________________",
              "has_free_text": true
            },
            {
              "value": "not_applicable",
              "label": "Not applicable: _________________",
              "has_free_text": true
            }
          ],
          "notes": [
            "C",
            "D"
          ],
          "guidance": "For poorly differentiated (high-grade) neuroendocrine carcinomas arising in the small intestine or ampulla, the checklists for carcinomas of those organ sites should be used."
        },
        {
          "field_id": "histologic_grade_determination",
          "label": "Histologic Grade Determination",
          "required": true,
          "type": "free_text",
          "notes": [
            "D"
          ]
        },
        {
          "field_id": "mitotic_rate_and_or_ki_67_labeling_index_is_required_to_determine_histologic_grade",
          "label": "Mitotic rate and / or Ki-67 labeling index is required to determine histologic grade",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "mitotic_rate_required_only_when_ki_67_labeling_index_is_not_reported",
          "label": "Mitotic Rate (required only when Ki-67 labeling index is not reported)#",
          "required": true,
          "type": "free_text",
          "guidance": "Mitotic rate should be reported as number of mitoses per 2 mm2, by evaluating at least 10 mm2 in the most"
        },
        {
          "field_id": "mitotically_active_part_of_the_tumor_eg_if_using_a_microscope_with_a_field_diameter_of_055_mm_count_",
          "label": "mitotically active part of the tumor (e.g., if using a microscope with a field diameter of 0.55 mm, count 42 high",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "power_fields_10_mm2_and_divide_the_resulting_number_of_mitoses_by_5_to_determine_the_number_of_mitos",
          "label": "power fields (10 mm2) and divide the resulting number of mitoses by 5 to determine the number of mitoses per 2",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "mm2_needed_to_assign_tumor_grade",
          "label": "mm2 needed to assign tumor grade).",
          "required": true,
          "type": "single_select",
          "options": [
            {
              "value": "not_applicable",
              "label": "Not applicable (Ki-67 labeling index is reported)"
            },
            {
              "value": "specify_number_of_mitoses_per_2_mm2",
              "label": "Specify number of mitoses per 2 mm2: _________________ mitoses per 2 mm2",
              "has_free_text": true
            },
            {
              "value": "less_than_2_mitoses_per_2_mm2",
              "label": "Less than 2 mitoses per 2 mm2"
            },
            {
              "value": "2_to_20_mitoses_per_2_mm2",
              "label": "2 to 20 mitoses per 2 mm2"
            },
            {
              "value": "greater_than_20_mitoses_per_2_mm2",
              "label": "Greater than 20 mitoses per 2 mm2"
            },
            {
              "value": "cannot_be_determined",
              "label": "Cannot be determined (explain): _________________",
              "has_free_text": true
            }
          ]
        },
        {
          "field_id": "ki_67_labeling_index",
          "label": "Ki-67 Labeling Index",
          "required": true,
          "type": "single_select",
          "options": [
            {
              "value": "not_applicable",
              "label": "Not applicable (mitotic rate is reported)"
            },
            {
              "value": "specify_ki_67_percentage",
              "label": "Specify Ki-67 percentage: _________________ %",
              "has_free_text": true
            },
            {
              "value": "less_than_3",
              "label": "Less than 3%"
            },
            {
              "value": "3_to_20",
              "label": "3% to 20%"
            },
            {
              "value": "greater_than_20",
              "label": "Greater than 20%"
            },
            {
              "value": "cannot_be_determined",
              "label": "Cannot be determined (explain): _________________",
              "has_free_text": true
            }
          ],
          "condition": "required only when mitotic rate is not reported"
        },
        {
          "field_id": "tumor_size",
          "label": "Tumor Size",
          "required": true,
          "type": "free_text",
          "notes": [
            "E"
          ]
        },
        {
          "field_id": "specify_size_of_largest_tumor_if_multiple_tumors_are_present",
          "label": "Specify size of largest tumor if multiple tumors are present",
          "required": true,
          "type": "single_select",
          "options": [
            {
              "value": "greatest_dimension_in_centimeters",
              "label": "Greatest dimension in Centimeters (cm): _________________ cm",
              "has_free_text": true
            }
          ]
        },
        {
          "field_id": "additional_dimension_in_centimeters_cm______x______cm",
          "label": "Additional Dimension in Centimeters (cm): ____ x ____ cm",
          "required": false,
          "type": "single_select",
          "options": [
            {
              "value": "cannot_be_determined",
              "label": "Cannot be determined (explain): _________________",
              "has_free_text": true
            }
          ]
        },
        {
          "field_id": "tumor_focality",
          "label": "Tumor Focality",
          "required": true,
          "type": "single_select",
          "options": [
            {
              "value": "unifocal",
              "label": "Unifocal"
            },
            {
              "value": "multifocal",
              "label": "Multifocal"
            }
          ]
        },
        {
          "field_id": "number_of_tumors",
          "label": "Number of Tumors",
          "required": true,
          "type": "single_select",
          "options": [
            {
              "value": "specify_number",
              "label": "Specify number: _________________",
              "has_free_text": true
            },
            {
              "value": "other",
              "label": "Other (specify): _________________",
              "has_free_text": true
            },
            {
              "value": "cannot_be_determined",
              "label": "Cannot be determined: _________________",
              "has_free_text": true
            },
            {
              "value": "cannot_be_determined",
              "label": "Cannot be determined: _________________",
              "has_free_text": true
            }
          ]
        },
        {
          "field_id": "tumor_extent",
          "label": "Tumor Extent",
          "required": true,
          "type": "single_select",
          "options": [
            {
              "value": "invades_lamina_propria",
              "label": "Invades lamina propria"
            },
            {
              "value": "invades_submucosa",
              "label": "Invades submucosa"
            },
            {
              "value": "invades_muscularis_propria",
              "label": "Invades muscularis propria"
            },
            {
              "value": "invades_through_muscularis_propria_into_subserosal_tissue_without_penetration_of_overlying_serosa",
              "label": "Invades through muscularis propria into subserosal tissue without penetration of overlying serosa"
            },
            {
              "value": "invades_visceral_peritoneum",
              "label": "Invades visceral peritoneum (serosa)"
            },
            {
              "value": "invades_other_organ",
              "label": "Invades other organ(s) or adjacent structure(s) (specify): _________________",
              "has_free_text": true
            },
            {
              "value": "cannot_be_determined",
              "label": "Cannot be determined: _________________",
              "has_free_text": true
            },
            {
              "value": "no_evidence_of_primary_tumor",
              "label": "No evidence of primary tumor"
            }
          ]
        },
        {
          "field_id": "lymphatic_and_or_vascular_invasion",
          "label": "Lymphatic and / or Vascular Invasion",
          "required": true,
          "type": "single_select",
          "options": [
            {
              "value": "not_identified",
              "label": "Not identified"
            },
            {
              "value": "present",
              "label": "Present"
            },
            {
              "value": "cannot_be_determined",
              "label": "Cannot be determined: _________________",
              "has_free_text": true
            }
          ]
        },
        {
          "field_id": "perineural_invasion",
          "label": "Perineural Invasion",
          "required": false,
          "type": "single_select",
          "options": [
            {
              "value": "not_identified",
              "label": "Not identified"
            },
            {
              "value": "present",
              "label": "Present"
            },
            {
              "value": "cannot_be_determined",
              "label": "Cannot be determined: _________________",
              "has_free_text": true
            }
          ]
        },
        {
          "field_id": "large_mesenteric_masses",
          "label": "Large Mesenteric Masses",
          "required": true,
          "type": "single_select",
          "options": [
            {
              "value": "not_identified",
              "label": "Not identified"
            },
            {
              "value": "present",
              "label": "Present"
            }
          ],
          "notes": [
            "G"
          ],
          "condition": "greater than 2 cm"
        },
        {
          "field_id": "number_of_large_mesenteric_masses",
          "label": "Number of Large Mesenteric Masses",
          "required": false,
          "type": "single_select",
          "options": [
            {
              "value": "specify_number",
              "label": "Specify number: _________________",
              "has_free_text": true
            },
            {
              "value": "other",
              "label": "Other (specify): _________________",
              "has_free_text": true
            },
            {
              "value": "cannot_be_determined",
              "label": "Cannot be determined: _________________",
              "has_free_text": true
            },
            {
              "value": "cannot_be_determined",
              "label": "Cannot be determined: _________________",
              "has_free_text": true
            }
          ]
        },
        {
          "field_id": "tumor_comment",
          "label": "Tumor Comment: _________________",
          "required": false,
          "type": "free_text"
        },
        {
          "field_id": "margins",
          "label": "MARGINS",
          "required": true,
          "type": "free_text",
          "notes": [
            "F"
          ]
        },
        {
          "field_id": "margin_status",
          "label": "Margin Status",
          "required": true,
          "type": "single_select",
          "options": [
            {
              "value": "all_margins_negative_for_tumor",
              "label": "All margins negative for tumor"
            }
          ]
        },
        {
          "field_id": "closest_margins_to_tumor",
          "label": "Closest Margin(s) to Tumor",
          "required": false,
          "type": "multi_select",
          "options": [
            {
              "value": "proximal",
              "label": "Proximal: _________________",
              "has_free_text": true
            },
            {
              "value": "distal",
              "label": "Distal: _________________",
              "has_free_text": true
            },
            {
              "value": "radial",
              "label": "Radial: _________________",
              "has_free_text": true
            },
            {
              "value": "mesenteric",
              "label": "Mesenteric: _________________",
              "has_free_text": true
            },
            {
              "value": "other",
              "label": "Other (specify): _________________",
              "has_free_text": true
            },
            {
              "value": "cannot_be_determined",
              "label": "Cannot be determined: _________________",
              "has_free_text": true
            }
          ]
        },
        {
          "field_id": "distance_from_tumor_to_closest_margin",
          "label": "Distance from Tumor to Closest Margin",
          "required": false,
          "type": "free_text"
        },
        {
          "field_id": "specify_in_centimeters",
          "label": "Specify in Centimeters",
          "required": true,
          "type": "single_select",
          "options": [
            {
              "value": "exact_distance_in_cm",
              "label": "Exact distance in cm: _________________ cm",
              "has_free_text": true
            },
            {
              "value": "greater_than_1_cm",
              "label": "Greater than 1 cm"
            }
          ],
          "condition": "cm"
        },
        {
          "field_id": "specify_in_millimeters",
          "label": "Specify in Millimeters",
          "required": true,
          "type": "single_select",
          "options": [
            {
              "value": "exact_distance_in_mm",
              "label": "Exact distance in mm: _________________ mm",
              "has_free_text": true
            },
            {
              "value": "greater_than_10_mm",
              "label": "Greater than 10 mm"
            }
          ],
          "condition": "mm"
        },
        {
          "field_id": "other",
          "label": "Other",
          "required": true,
          "type": "single_select",
          "options": [
            {
              "value": "other",
              "label": "Other (specify): _________________",
              "has_free_text": true
            },
            {
              "value": "cannot_be_determined",
              "label": "Cannot be determined: _________________",
              "has_free_text": true
            },
            {
              "value": "tumor_present_at_margin",
              "label": "Tumor present at margin"
            }
          ]
        },
        {
          "field_id": "margins_involved_by_tumor",
          "label": "Margin(s) Involved by Tumor",
          "required": true,
          "type": "multi_select",
          "options": [
            {
              "value": "proximal",
              "label": "Proximal: _________________",
              "has_free_text": true
            },
            {
              "value": "distal",
              "label": "Distal: _________________",
              "has_free_text": true
            },
            {
              "value": "radial",
              "label": "Radial: _________________",
              "has_free_text": true
            },
            {
              "value": "mesenteric",
              "label": "Mesenteric: _________________",
              "has_free_text": true
            },
            {
              "value": "other",
              "label": "Other (specify): _________________",
              "has_free_text": true
            },
            {
              "value": "cannot_be_determined",
              "label": "Cannot be determined: _________________",
              "has_free_text": true
            },
            {
              "value": "other",
              "label": "Other (specify): _________________",
              "has_free_text": true
            },
            {
              "value": "cannot_be_determined",
              "label": "Cannot be determined (explain): _________________",
              "has_free_text": true
            },
            {
              "value": "not_applicable",
              "label": "Not applicable"
            }
          ]
        },
        {
          "field_id": "margin_comment",
          "label": "Margin Comment: _________________",
          "required": false,
          "type": "free_text"
        }
      ]
    },
    {
      "section_id": "regional_lymph_nodes",
      "section_name": "REGIONAL LYMPH NODES",
      "fields": [
        {
          "field_id": "regional_lymph_node_status",
          "label": "Regional Lymph Node Status",
          "required": true,
          "type": "single_select",
          "options": [
            {
              "value": "not_applicable",
              "label": "Not applicable (no regional lymph nodes submitted or found)"
            },
            {
              "value": "regional_lymph_nodes_present",
              "label": "Regional lymph nodes present"
            },
            {
              "value": "all_regional_lymph_nodes_negative_for_tumor",
              "label": "All regional lymph nodes negative for tumor"
            },
            {
              "value": "tumor_present_in_regional_lymph_node",
              "label": "Tumor present in regional lymph node(s)"
            }
          ]
        },
        {
          "field_id": "number_of_lymph_nodes_with_tumor",
          "label": "Number of Lymph Nodes with Tumor",
          "required": true,
          "type": "single_select",
          "options": [
            {
              "value": "exact_number",
              "label": "Exact number (specify): _________________",
              "has_free_text": true
            },
            {
              "value": "at_least",
              "label": "At least (specify): _________________",
              "has_free_text": true
            },
            {
              "value": "other",
              "label": "Other (specify): _________________",
              "has_free_text": true
            },
            {
              "value": "cannot_be_determined",
              "label": "Cannot be determined (explain): _________________",
              "has_free_text": true
            },
            {
              "value": "other",
              "label": "Other (specify): _________________",
              "has_free_text": true
            },
            {
              "value": "cannot_be_determined",
              "label": "Cannot be determined (explain): _________________",
              "has_free_text": true
            }
          ]
        },
        {
          "field_id": "number_of_lymph_nodes_examined",
          "label": "Number of Lymph Nodes Examined",
          "required": true,
          "type": "single_select",
          "options": [
            {
              "value": "exact_number",
              "label": "Exact number (specify): _________________",
              "has_free_text": true
            },
            {
              "value": "at_least",
              "label": "At least (specify): _________________",
              "has_free_text": true
            },
            {
              "value": "other",
              "label": "Other (specify): _________________",
              "has_free_text": true
            },
            {
              "value": "number_cannot_be_determined",
              "label": "Number cannot be determined (explain): _________________",
              "has_free_text": true
            }
          ]
        },
        {
          "field_id": "regional_lymph_node_comment",
          "label": "Regional Lymph Node Comment: _________________",
          "required": false,
          "type": "free_text"
        }
      ]
    },
    {
      "section_id": "distant_metastasis",
      "section_name": "DISTANT METASTASIS",
      "fields": [
        {
          "field_id": "distant_sites_involved_if_applicable",
          "label": "Distant Site(s) Involved, if applicable",
          "required": true,
          "type": "multi_select",
          "options": [
            {
              "value": "not_applicable",
              "label": "Not applicable"
            },
            {
              "value": "liver",
              "label": "Liver: _________________",
              "has_free_text": true
            },
            {
              "value": "lung",
              "label": "Lung: _________________",
              "has_free_text": true
            },
            {
              "value": "ovary",
              "label": "Ovary: _________________",
              "has_free_text": true
            },
            {
              "value": "nonregional_lymph_node",
              "label": "Nonregional lymph node(s): _________________",
              "has_free_text": true
            },
            {
              "value": "peritoneum",
              "label": "Peritoneum: _________________",
              "has_free_text": true
            },
            {
              "value": "bone",
              "label": "Bone: _________________",
              "has_free_text": true
            },
            {
              "value": "other",
              "label": "Other (specify): _________________",
              "has_free_text": true
            },
            {
              "value": "cannot_be_determined",
              "label": "Cannot be determined: _________________",
              "has_free_text": true
            }
          ]
        },
        {
          "field_id": "ptnm_classification",
          "label": "pTNM CLASSIFICATION",
          "required": true,
          "type": "free_text",
          "notes": [
            "G"
          ],
          "condition": "AJCC Version 9"
        },
        {
          "field_id": "modified_classification_required_only_if_applicable",
          "label": "Modified Classification (required only if applicable)",
          "required": true,
          "type": "multi_select",
          "options": [
            {
              "value": "not_applicable",
              "label": "Not applicable"
            },
            {
              "value": "y",
              "label": "y (post-neoadjuvant therapy)"
            },
            {
              "value": "r",
              "label": "r (recurrence)"
            },
            {
              "value": "pt_not_assigned",
              "label": "pT not assigned (cannot be determined based on available pathological information)"
            },
            {
              "value": "pt0",
              "label": "pT0: No evidence of primary tumor"
            },
            {
              "value": "pt1",
              "label": "pT1: Tumor invades mucosa or submucosa, and is less than or equal to 1 cm in greatest dimension"
            },
            {
              "value": "pt2",
              "label": "pT2: Tumor invades muscularis propria or greater than 1 cm in greatest dimension"
            },
            {
              "value": "pt3",
              "label": "pT3: Tumor invades through the muscularis propria into subserosal tissue without penetration of"
            }
          ],
          "guidance": "Multiple tumors should be designated as such (the largest tumor should be used to assign T category). Use T(#); e.g., pT3(4) N0 M0, OR use the m suffix, T(m); e.g., pT3(m) N0 M0."
        },
        {
          "field_id": "overlying_serosa",
          "label": "overlying serosa",
          "required": true,
          "type": "single_select",
          "options": [
            {
              "value": "pt4",
              "label": "pT4: Tumor invades the visceral peritoneum (serosal) or other organs or adjacent structures"
            }
          ]
        },
        {
          "field_id": "t_suffix",
          "label": "T Suffix",
          "required": true,
          "type": "single_select",
          "options": [
            {
              "value": "not_applicable",
              "label": "Not applicable"
            },
            {
              "value": "",
              "label": "(m) multiple primary synchronous tumors in a single organ"
            }
          ],
          "condition": "required only if applicable"
        },
        {
          "field_id": "pn_category",
          "label": "pN Category",
          "required": true,
          "type": "single_select",
          "options": [
            {
              "value": "pn_not_assigned",
              "label": "pN not assigned (no nodes submitted or found)"
            },
            {
              "value": "pn_not_assigned",
              "label": "pN not assigned (cannot be determined based on available pathological information)"
            },
            {
              "value": "pn0",
              "label": "pN0: No tumor involvement of regional lymph node(s)"
            },
            {
              "value": "pn1",
              "label": "pN1: Tumor involvement of less than 12 regional lymph nodes"
            },
            {
              "value": "pn2",
              "label": "pN2: Tumor involvement of large mesenteric masses (greater than 2 cm) and / or extensive nodal"
            }
          ],
          "guidance": "Mesenteric masses less than or equal to 2 cm should be stated in the pathology report as being present and collected by registrars but do not affect the stage."
        },
        {
          "field_id": "deposits_12_or_greater_especially_those_that_encase_the_superior_mesenteric_vessels",
          "label": "deposits (12 or greater), especially those that encase the superior mesenteric vessels#",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "pm_category",
          "label": "pM Category",
          "required": true,
          "type": "single_select",
          "options": [
            {
              "value": "not_applicable_pm_cannot_be_determined_from_the_submitted_specimen",
              "label": "Not applicable - pM cannot be determined from the submitted specimen(s)"
            }
          ],
          "condition": "required only if confirmed pathologically"
        },
        {
          "field_id": "pm1_microscopic_confirmation_of_distant_metastasis",
          "label": "pM1: Microscopic confirmation of distant metastasis",
          "required": true,
          "type": "single_select",
          "options": [
            {
              "value": "pm1a",
              "label": "pM1a: Microscopic confirmation of metastasis confined to liver"
            },
            {
              "value": "pm1b",
              "label": "pM1b: Microscopic confirmation of metastasis in at least one extrahepatic site (e.g., lung, ovary, nonregional lymph node, peritoneum, bone)"
            },
            {
              "value": "pm1c",
              "label": "pM1c: Microscopic confirmation of both hepatic and extrahepatic metastases"
            },
            {
              "value": "pm1",
              "label": "pM1 (subcategory cannot be determined)"
            }
          ]
        },
        {
          "field_id": "additional_findings",
          "label": "ADDITIONAL FINDINGS",
          "required": true,
          "type": "free_text",
          "notes": [
            "H"
          ]
        },
        {
          "field_id": "additional_findings",
          "label": "Additional Findings",
          "required": false,
          "type": "multi_select",
          "options": [
            {
              "value": "none_identified",
              "label": "None identified"
            },
            {
              "value": "tumor_necrosis",
              "label": "Tumor necrosis"
            },
            {
              "value": "mesenteric_tumor_deposit",
              "label": "Mesenteric tumor deposit(s) less than or equal to 2 cm"
            },
            {
              "value": "intestinal_ischemia_necrosis",
              "label": "Intestinal ischemia / necrosis"
            },
            {
              "value": "mesenteric_vascular_elastosis",
              "label": "Mesenteric vascular elastosis"
            },
            {
              "value": "other",
              "label": "Other (specify): _________________",
              "has_free_text": true
            }
          ]
        }
      ]
    },
    {
      "section_id": "comments",
      "section_name": "COMMENTS",
      "fields": [
        {
          "field_id": "comments",
          "label": "Comment(s): _________________",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "explanatory_notes",
          "label": "Explanatory Notes",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "this_protocol_applies_to_well_differentiated_neuroendocrine_tumors_carcinoid_tumors_of_the_jejunum_a",
          "label": "This protocol applies to well-differentiated neuroendocrine tumors (carcinoid tumors) of the jejunum and ileum.",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "this_protocol_can_be_used_for_tumors_involving_overlapping_sites_in_the_small_intestine_or_when_the_",
          "label": "This protocol can be used for tumors involving overlapping sites in the small intestine or when the site is unclear. For tumors of the duodenum and ampulla use separate protocol created for these sites.  Poorly differentiated neuroendocrine carcinomas (small cell carcinomas and large cell neuroendocrine carcinomas) and tumors with mixed glandular/neuroendocrine differentiation are not included.1 Neuroendocrine tumors of the duodenum and ampulla of Vater use a separate CAP cancer protocol2.",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "because_of_site_specific_similarities_in_histology_immunohistochemistry_and_histochemistry_neuroendo",
          "label": "Because of site-specific similarities in histology, immunohistochemistry, and histochemistry, neuroendocrine tumors of the digestive tract have traditionally been subdivided into those of foregut, midgut, and hindgut origin (Table 1). In general, the distribution pattern along the gastrointestinal (GI) tract parallels that of the progenitor cell type, and the anatomic site of origin of GI neuroendocrine tumors is an important predictor of clinical behavior.3",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "table_1_site_of_origin_of_gastrointestinal_neuroendocrine_tumors",
          "label": "Table 1. Site of Origin of Gastrointestinal Neuroendocrine Tumors",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "references",
          "label": "References",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "burghart_l_chopp_wv_jain_d_examination_of_specimens_from_patients_with_carcinoma_of_small_intestine_",
          "label": "Burghart L, Chopp WV, Jain D. Examination of Specimens From Patients With Carcinoma of Small Intestine. 2021. Available at www.cap.org/cancerprotocols.",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "jain_d_chopp_wv_graham_rp_protocol_for_the_examination_of_specimens_from_patients_with_neuroendocrin",
          "label": "Jain D, Chopp WV, Graham RP. Protocol for the Examination of Specimens From Patients With Neuroendocrine Tumors of the Duodenum and Ampulla. 2023. Available at www.cap.org/cancerprotocols.",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "rorstad_o_prognostic_indicators_for_carcinoid_neuroendocrine_tumors_of_the_gastrointestinal_tract_j_",
          "label": "Rorstad O. Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract. J Surg Oncol. 2005;89(3):151-160.",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "eckhauser_fe_argenta_lc_strodel_we_et_al_mesenteric_angiopathy_intestinal_gangrene_and_midgut_carcin",
          "label": "Eckhauser FE, Argenta LC, Strodel WE, et al. Mesenteric angiopathy, intestinal gangrene, and midgut carcinoids. Surgery. 1981;90(4):720-728.",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "modlin_im_lye_kd_kidd_m_a_5_decade_analysis_of_13715_carcinoid_tumors_cancer_2003974934_959",
          "label": "Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97(4):934-959.",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "graeme_cook_f_neuroendocrine_tumors_of_the_gi_tract_and_appendix_in_odze_rd_goldblum_jr_crawford_jm_",
          "label": "Graeme-Cook F. Neuroendocrine tumors of the GI tract and appendix. In: Odze RD, Goldblum JR, Crawford JM, eds. Surgical Pathology of the GI Tract, Liver, Biliary Tract, and Pancreas. Philadelphia, PA: Saunders; 2004: 483-504.",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "anlauf_m_n_garbrecht_t_henopp_a_schmitt_r_schlenger_a_raffel_m_krausch_et_al_sporadic_versus_heredit",
          "label": "Anlauf, M., N. Garbrecht, T. Henopp, A. Schmitt, R. Schlenger, A. Raffel, M. Krausch, et al. 'Sporadic Versus Hereditary Gastrinomas of the Duodenum and Pancreas: Distinct Clinico-Pathological and Epidemiological Features.' World J Gastroenterol 12, no. 34 (Sep 14 2006): 5440-5446",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "eckhauser_fe_argenta_lc_strodel_we_et_al_mesenteric_angiopathy_intestinal_gangrene_and_midgut_carcin",
          "label": "Eckhauser FE, Argenta LC, Strodel WE, et al. Mesenteric angiopathy, intestinal gangrene, and midgut carcinoids. Surgery. 1981;90(4):720-728.",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "kimura_n_sasano_n_prostate_specific_acid_phosphatase_in_carcinoid_tumors_virchows_arch_a_pathol_anat",
          "label": "Kimura N, Sasano N. Prostate-specific acid phosphatase in carcinoid tumors. Virchows Arch A Pathol Anat Histopathol. 1986;410(3):247-251.",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "nash_sv_said_jw_gastroenteropancreatic_neuroendocrine_tumors_a_histochemical_and_immunohistochemical",
          "label": "Nash SV, Said JW. Gastroenteropancreatic neuroendocrine tumors: a histochemical and immunohistochemical study of epithelial (keratin proteins, carcinoembryonic antigen) and neuroendocrine (neuron-specific enolase, bombesin and chromogranin) markers in foregut, midgut, and hindgut tumors. Am J Clin Pathol. 1986;86(2):415-422.",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "williams_gt_endocrine_tumours_of_the_gastrointestinal_tract_selected_topics_histopathology_200750130",
          "label": "Williams GT. Endocrine tumours of the gastrointestinal tract: selected topics. Histopathology. 2007;50(1):30-41.",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "garbrecht_n_anlauf_m_schmitt_a_et_al_somatostatin_producing_neuroendocrine_tumors_of_the_duodenum_an",
          "label": "Garbrecht N, Anlauf M, Schmitt A, et al. Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndromes, and functional activity. Endocr Rel Cancer. 2008;15(1):229-241.",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "the_small_intestine_is_the_most_common_primary_site_for_neuroendocrine_tumors123_most_small_intestin",
          "label": "The small intestine is the most common primary site for neuroendocrine tumors.1,2,3 Most small intestine neuroendocrine tumors occur in the distal ileum. Multiple tumors are found in 25% to 40% of cases and may be associated with a worse outcome.4 Primary jejunal and ileal tumors are often small and asymptomatic. However, extensive fibrosis can form when they invade deep soft tissue (e.g., mesenteric soft tissue), causing small bowel obstruction and small bowel ischemia due to encasement of the superior mesenteric vessels. In addition, about 50% of patients with jejunoileal neuroendocrine tumor have liver metastasis as the initial presentation, and patients with liver metastasis can have carcinoid syndrome (e.g., flushing, diarrhea, and wheezing). Metastatic risk is increased by tumor size >2 cm, involvement of the muscularis propria, and mitotic activity.5,6",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "references",
          "label": "References",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "modlin_im_lye_kd_kidd_m_a_5_decade_analysis_of_13715_carcinoid_tumors_cancer_2003974934_959",
          "label": "Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97(4):934-959.",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "graeme_cook_f_neuroendocrine_tumors_of_the_gi_tract_and_appendix_in_odze_rd_goldblum_jr_crawford_jm_",
          "label": "Graeme-Cook F. Neuroendocrine tumors of the GI tract and appendix. In: Odze RD, Goldblum JR, Crawford JM, eds. Surgical Pathology of the GI Tract, Liver, Biliary Tract, and Pancreas. Philadelphia, PA: Saunders; 2004: 483-504.",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "williams_gt_endocrine_tumours_of_the_gastrointestinal_tract_selected_topics_histopathology_200750130",
          "label": "Williams GT. Endocrine tumours of the gastrointestinal tract: selected topics. Histopathology. 2007;50(1):30-41.",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "yantiss_rk_odze_rd_farraye_fa_rosenberg_ae_solitary_versus_multiple_carcinoid_tumors_of_the_ileum_a_",
          "label": "Yantiss RK, Odze RD, Farraye FA, Rosenberg AE. Solitary versus multiple carcinoid tumors of the ileum: a clinical and pathologic review of 69 cases. Am J Surg Pathol. 2003;27(6):811-817.",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "nash_sv_said_jw_gastroenteropancreatic_neuroendocrine_tumors_a_histochemical_and_immunohistochemical",
          "label": "Nash SV, Said JW. Gastroenteropancreatic neuroendocrine tumors: a histochemical and immunohistochemical study of epithelial (keratin proteins, carcinoembryonic antigen) and neuroendocrine (neuron-specific enolase, bombesin and chromogranin) markers in foregut, midgut, and hindgut tumors. Am J Clin Pathol. 1986;86(2):415-422.",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "rorstad_o_prognostic_indicators_for_carcinoid_neuroendocrine_tumors_of_the_gastrointestinal_tract_j_",
          "label": "Rorstad O. Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract. J Surg Oncol. 2005;89(3):151-160.",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "the_world_health_organization_who_classifies_neuroendocrine_neoplasms_as_well_differentiated_neuroen",
          "label": "The World Health Organization (WHO) classifies neuroendocrine neoplasms as well-differentiated neuroendocrine tumors (either the primary tumor or metastasis) and poorly differentiated neuroendocrine carcinomas.1 Historically, well-differentiated neuroendocrine tumors have been referred to as “carcinoid tumors,” a term which may cause confusion because clinically a carcinoid tumor is a serotonin-producing tumor associated with functional manifestations of carcinoid syndrome. The use of the term “carcinoid” for neuroendocrine tumor reporting is therefore discouraged for these reasons.",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "classification_of_neuroendocrine_tumors_is_based_upon_size_functionality_site_and_invasion_functioni",
          "label": "Classification of neuroendocrine tumors is based upon size, functionality, site, and invasion.  Functioning tumors are those associated with clinical manifestations of hormone production or secretion of measurable amounts of active hormone; immunohistochemical demonstration of hormone production is not equivalent to clinically apparent functionality.",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "immunohistochemistry_and_other_ancillary_techniques_are_generally_not_required_to_diagnose_well_diff",
          "label": "Immunohistochemistry and other ancillary techniques are generally not required to diagnose well-differentiated neuroendocrine tumors.  Specific markers that may be used to establish neuroendocrine differentiation include chromogranin A, synaptophysin, INSM1 and CD56.2 Because of their relative sensitivity and specificity, chromogranin A and synaptophysin are recommended, although INSIM1 is also emerging as a good marker for endocrine differentiation.3,4",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "references",
          "label": "References",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "who_classification_of_tumours_editorial_board_digestive_system_tumours_lyon_france_international_age",
          "label": "WHO Classification of Tumours Editorial Board. Digestive system tumours. Lyon (France): International Agency for Research on Cancer; 2019. (WHO classification of tumours series, 5th ed.; vol. 1).",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "williams_gt_endocrine_tumours_of_the_gastrointestinal_tract_selected_topics_histopathology_200750130",
          "label": "Williams GT. Endocrine tumours of the gastrointestinal tract: selected topics. Histopathology. 2007;50(1):30-41.",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "zhang_q_huang_j_he_y_cao_r_shu_j_insulinoma_associated_protein_1insm1_is_a_superior_marker_for_the_d",
          "label": "Zhang Q, Huang J, He Y, Cao R, Shu J. Insulinoma-associated protein 1(INSM1) is a superior marker for the diagnosis of gastroenteropancreatic neuroendoerine neoplasms: a meta-analysis. Endocrine. 2021;74(1):61-71.",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "mchugh_ke_mukhopadhyay_s_doxtader_ee_lanigan_c_allende_ds_insm1_is_a_highly_specific_marker_of_neuro",
          "label": "McHugh KE, Mukhopadhyay S, Doxtader EE, Lanigan C, Allende DS. INSM1 Is a Highly Specific Marker of Neuroendocrine Differentiation in Primary Neoplasms of the Gastrointestinal Tract, Appendix, and Pancreas. Am J Clin Pathol. 2020;153(6):811-820.",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "cytologic_atypia_in_well_differentiated_neuroendocrine_tumors_has_no_impact_on_clinical_behavior_of_",
          "label": "Cytologic atypia in well-differentiated neuroendocrine tumors has no impact on clinical behavior of these tumors.",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "the_who_classification1_and_others2_use_mitotic_rate_andor_ki_67_index_as_one_of_the_criteria_for_po",
          "label": "The WHO classification1 and others2 use mitotic rate and/or Ki-67 index as one of the criteria for potential for aggressive behavior.  Mitotic rate should be reported as number of mitoses per 2 mm2, by evaluating at least 10 mm2 in the most mitotically active part of the tumor. Only clearly identifiable mitotic figures should be counted; hyperchromatic, karyorrhectic, or apoptotic nuclei are excluded. Because of variations in field size, the number of high-power field (HPF) (at 40X magnification) for 10 mm2 (thereby 2 mm2) must be determined for each microscope (Table 2). For example, if using a microscope with a field diameter of 0.55 mm, count 42 HPF and divide the resulting number of mitoses by 5 to determine the number of mitoses per 2 mm2  needed to assign tumor grade.",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "table_2_number_of_hpf_required_for_10_mm2_using_microscopes_with_different_field_diameter",
          "label": "Table 2. Number of HPF Required for 10 mm2 Using Microscopes With Different Field Diameter",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "ki_67_index_is_reported_as_percent_positive_tumor_cells_in_area_of_highest_nuclear_labeling_hot_spot",
          "label": "Ki-67 index is reported as percent positive tumor cells in area of highest nuclear labeling (“hot spot”), although the precise method of assessment has not been standardized. A number of methods have used to assess Ki-67 index, including automatic counting and “eyeballing.”3,4 Automated counting is not widely available and requires careful modification of the software to circumvent the inaccuracies.3 Eye-balling can be used for most tumors; however, for tumors with Ki-67 index close to grade cut-offs, it is recommended to perform the manual count on the print of camera-captured image of the hot spot. It has been recommended that a minimum of 500 tumor cells be counted to determine the Ki-67 index, and a notation is made if less cells are available. Grade assigned based on Ki-67 index is typically higher than that based on mitotic count, and the case is assigned to the higher of the 2 if both methods are performed.1",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "it_is_important_to_note_that_there_are_a_small_group_of_well_differentiated_neuroendocrine_tumors_wi",
          "label": "It is important to note that there are a small group of well-differentiated neuroendocrine tumors with a Ki-67 index >20% and a mitotic rate usually <20 per 10 HPF. In WHO-2010, these tumors were considered as G3 poorly differentiated neuroendocrine carcinomas. However, they have typical morphology of well-differentiated tumors.",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "previous_studies_most_on_pancreatic_neuroendocrine_tumors_have_demonstrated_that_these_tumors_have_a",
          "label": "Previous studies (most on pancreatic neuroendocrine tumors) have demonstrated that these tumors have a worse prognosis than grade 2 (Ki-67=3-20% and mitosis <20/10 HPF) neuroendocrine tumors, but they are not as aggressive as poorly differentiated neuroendocrine carcinomas.5 In addition, these tumors do not have the genetic abnormalities seen in poorly differentiated neuroendocrine carcinomas.6 Furthermore, unlike poorly differentiated neuroendocrine carcinomas, they are less responsive to platinum-based chemotherapy.7 In the WHO-2019 blue book of digestive system tumor and AJCC Version 9, those with typical morphology of well-differentiated tumors are classified as “well differentiated neuroendocrine tumor” but as grade 3 (Table 3) and increasingly recognized, even in small intestine.5,6,7,8",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "table_3_recommended_grading_system_for_well_differentiated_gastroenteropancreatic_neuroendocrine_tum",
          "label": "Table 3. Recommended Grading System for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "references",
          "label": "References",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "who_classification_of_tumours_editorial_board_digestive_system_tumours_lyon_france_international_age",
          "label": "WHO Classification of Tumours Editorial Board. Digestive system tumours. Lyon (France): International Agency for Research on Cancer; 2019. (WHO classification of tumours series, 5th ed.; vol. 1).",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "rindi_g_kloppel_g_alhman_h_et_al_and_all_other_frascati_consensus_conference_participants_european_n",
          "label": "Rindi G, Kloppel G, Alhman H, et al; and all other Frascati Consensus Conference participants; European Neuroendocrine Tumor Society (ENETS). TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006;449(4):395-401.",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "tang_lh_gonen_m_hedvat_c_modlin_i_klimstra_ds_objective_quantification_of_the_ki_67_proliferative_in",
          "label": "Tang LH, Gonen M, Hedvat C, Modlin I, Klimstra DS. Objective quantification of the Ki-67 proliferative index in neuroendocrine tumors of gastroenteropancreatic system: a comparison of digital image analysis with manual methods. Am J Surg Pathol. 2012;36(12):1761-1770.",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "reid_md_bagci_p_ohike_n_et_al_calculation_of_the_ki67_index_in_pancreatic_neuroendocrine_tumors_a_co",
          "label": "Reid MD, Bagci P, Ohike N, et al. Calculation of the Ki67 index in pancreatic neuroendocrine tumors: a comparative analysis of four counting methodologies. Mod Pathol. 2016;29(1):93.",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "shi_c_klimstra_ds_pancreatic_neuroendocrine_tumors_pathologic_and_molecular_characteristics_semin_di",
          "label": "Shi C, Klimstra DS. Pancreatic neuroendocrine tumors: pathologic and molecular characteristics. Semin Diagn Pathol. 2014;31(6):498-511.",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "yachida_s_vakiani_e_white_cm_et_al_small_cell_and_large_cell_neuroendocrine_carcinomas_of_the_pancre",
          "label": "Yachida S, Vakiani E, White CM, et al. Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol. 2012;36(2):173-184.",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "sorbye_h_strosberg_j_baudin_e_klimstra_ds_yao_jc_gastroenteropancreatic_high_grade_neuroendocrine_ca",
          "label": "Sorbye H, Strosberg J, Baudin E, Klimstra DS, Yao JC. Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer. 2014;120(18):2814-2823.",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "for_neuroendocrine_tumors_in_any_part_of_the_gastrointestinal_tract_size_greater_than_20_cm_is_assoc",
          "label": "For neuroendocrine tumors in any part of the gastrointestinal tract, size greater than 2.0 cm is associated with a higher risk of lymph node metastasis.  For jejunoileal tumors, nodal metastases occur in about 12% of patients with tumors smaller than 1.0 cm and in most patients with tumors larger than 1.0 cm.1 Thus, treatment for small intestine neuroendocrine tumor includes complete resection with regional lymphadenectomy.",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "references",
          "label": "References",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "rorstad_o_prognostic_indicators_for_carcinoid_neuroendocrine_tumors_of_the_gastrointestinal_tract_j_",
          "label": "Rorstad O. Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract. J Surg Oncol. 2005;89(3):151-160.",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "f_circumferential_radial_or_mesenteric_margin",
          "label": "F. Circumferential (Radial or Mesenteric) Margin",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "in_addition_to_addressing_the_proximal_and_distal_margins_assessment_of_the_circumferential_radial_m",
          "label": "In addition to addressing the proximal and distal margins, assessment of the circumferential (radial) margin is necessary for any segment of gastrointestinal tract either unencased (Figure, C) or incompletely encased by peritoneum (Figure, B). The circumferential margin represents the adventitial soft tissue margin closest to the deepest penetration of tumor and is created surgically by blunt or sharp dissection of the retroperitoneal or subperitoneal aspect, respectively.  The distance between the tumor and circumferential (radial) margin should be reported, if applicable. The circumferential (radial) margin is considered positive if the tumor is present at the inked nonperitonealized surface. This assessment includes tumor within a lymph node as well as direct tumor extension, but if circumferential (radial) margin positivity is based solely on intranodal tumor, this should be so stated.",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "the_mesenteric_resection_margin_is_the_only_relevant_circumferential_margin_in_segments_completely_e",
          "label": "The mesenteric resection margin is the only relevant circumferential margin in segments completely encased by peritoneum (e.g., jejunum and ileum) (Figure, A). Involvement of this margin should be reported even if tumor does not penetrate the serosal surface.",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "a_mesenteric_margin_in_viscus_completely_encased_by_peritoneum_dotted_line_b_circumferential_radial_",
          "label": "A: Mesenteric margin in viscus completely encased by peritoneum (dotted line).  B: Circumferential (radial) margin (dotted line) in viscus incompletely encased by peritoneum. C: Circumferential (radial) margin (dotted line) in viscus completely unencased by peritoneum.",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "the_tnm_staging_system_for_neuroendocrine_tumors_of_the_jejunum_and_ileum_of_the_american_joint_comm",
          "label": "The TNM staging system for neuroendocrine tumors of the jejunum and ileum of the American Joint Committee on Cancer (AJCC) and the International Union Against Cancer (UICC) is recommended.1",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "by_ajccuicc_convention_the_designation_t_refers_to_a_primary_tumor_that_has_not_been_previously_trea",
          "label": "By AJCC/UICC convention, the designation “T” refers to a primary tumor that has not been previously treated. The symbol “p” refers to the pathologic classification of the TNM, as opposed to the clinical classification, and is based on gross and microscopic examination. pT entails a resection of the primary tumor or biopsy adequate to evaluate the highest pT category, pN entails removal of nodes adequate to validate lymph node metastasis, and pM implies microscopic examination of distant lesions. Clinical classification (cTNM) is usually carried out by the referring physician before treatment during initial evaluation of the patient or when pathologic classification is not possible.",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "pathologic_staging_is_usually_performed_after_surgical_resection_of_the_primary_tumor_pathologic_sta",
          "label": "Pathologic staging is usually performed after surgical resection of the primary tumor. Pathologic staging depends on pathologic documentation of the anatomic extent of disease, whether or not the primary tumor has been completely removed. If a biopsied tumor is not resected for any reason (e.g., when technically unfeasible) and if the highest T and N categories or the M1 category of the tumor can be confirmed microscopically, the criteria for pathologic classification and staging have been satisfied without total removal of the primary cancer.",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "for_identification_of_special_cases_of_tnm_or_ptnm_classifications_the_m_suffix_and_y_r_and_a_prefix",
          "label": "For identification of special cases of TNM or pTNM classifications, the “m” suffix and “y,” “r,” and “a” prefixes are used. Although they do not affect the stage grouping, they indicate cases needing separate analysis.",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "the_m_suffix_indicates_the_presence_of_multiple_primary_tumors_in_a_single_site_and_is_recorded_in_p",
          "label": "The “m” suffix indicates the presence of multiple primary tumors in a single site and is recorded in parentheses: pT(m)NM.",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "the_y_prefix_indicates_those_cases_in_which_classification_is_performed_during_or_following_initial_",
          "label": "The “y” prefix indicates those cases in which classification is performed during or following initial multimodality therapy (i.e., neoadjuvant chemotherapy, radiation therapy, or both chemotherapy and radiation therapy). The cTNM or pTNM category is identified by a “y” prefix. The ycTNM or ypTNM categorizes the extent of tumor actually present at the time of that examination. The “y” categorization is not an estimate of tumor prior to multimodality therapy (i.e., before initiation of neoadjuvant therapy).",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "the_r_prefix_indicates_a_recurrent_tumor_when_staged_after_a_documented_disease_free_interval_and_is",
          "label": "The “r” prefix indicates a recurrent tumor when staged after a documented disease-free interval, and is identified by the “r” prefix: rTNM.",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "the_a_prefix_designates_the_stage_determined_at_autopsy_atnm",
          "label": "The “a” prefix designates the stage determined at autopsy: aTNM.",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "for_ileal_and_jejunal_tumors_the_regional_lymph_nodes_are_the_cecal_for_tumors_arising_in_the_termin",
          "label": "For ileal and jejunal tumors, the regional lymph nodes are the cecal (for tumors arising in the terminal ileum), superior mesenteric, and mesenteric nodes.  Metastases to celiac nodes are considered distant metastases.",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "mesenteric_masses_are_defined_as_discrete_but_irregular_mesenteric_tumor_nodules_frequently_located_",
          "label": "Mesenteric masses are defined as discrete but irregular mesenteric tumor nodules frequently located adjacent to neurovascular bundles and discontinuous from the primary neoplasm.2  Mesenteric masses result from extranodal extension or vascular/ pernineural spread of the tumor and are often associated with dense fibrosis, causing ecasement of large mesenteric vessels. The presence of mesenteric masses and nodal deposits in 12 or more nodes has been associated with frequent liver metastasis and a poor prognosis..2,3",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "the_liver_is_the_most_common_metastatic_site_metastases_to_extrahepatic_sites_such_as_lung_ovary_per",
          "label": "The liver is the most common metastatic site. Metastases to extrahepatic sites, such as lung, ovary, peritoneum, and bone, are rare. Involvement of the celiac, para-aortic, and other nonregional lymph nodes is also considered M1 disease. In the AJCC Version 9, M is subcategorized into M1a (hepatic only), M1b (extrahepatic only), and M1c (both hepatic and extrahepatic).",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "references",
          "label": "References",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "gonzalez_rs_liu_eh_alvarez_jr_ayers_gd_washington_mk_shi_c_should_mesenteric_tumor_deposits_be_inclu",
          "label": "Gonzalez RS, Liu EH, Alvarez JR, Ayers GD, Washington MK, Shi C. Should mesenteric tumor deposits be included in staging of well-differentiated small intestine neuroendocrine tumors? Mod Pathol. 2014;27(9):1288-1295.",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "fata_cr_gonzalez_rs_liu_e_et_al_mesenteric_tumor_deposits_in_midgut_small_intestinal_neuroendocrine_",
          "label": "Fata CR, Gonzalez RS, Liu E, et al. Mesenteric tumor deposits in midgut small intestinal neuroendocrine tumors are a stronger indicator than lymph node metastasis for liver metastasis and poor prognosis. Am J Surg Pathol. 2017;41(1):128-133.",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "mesenteric_fibrosis_is_seen_in_about_50_of_small_intestinal_neuroendocrine_tumors_and_leads_to_intes",
          "label": "Mesenteric fibrosis is seen in about 50% of small intestinal neuroendocrine tumors and leads to intestinal obstruction, intestinal ischemia, malabsorption, and malnutrition. Mesenteric vascular changes (elastic vascular sclerosis) associated with midgut carcinoids may produce arterial luminal narrowing due to concentric accumulation of elastic tissue in the adventitia.  These vascular changes may lead to intestinal ischemia and frank necrosis.1 While mesenteric fibrosis in stage IV tumors by itself does not significantly impact the overall, presence of mesenteric fibrosis along with vascular changes is indicative of an aggressive tumor biology and when leads to intestinal ischemia is associated with poor prognosis.2",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "references",
          "label": "References",
          "required": true,
          "type": "free_text"
        },
        {
          "field_id": "nash_sv_said_jw_gastroenteropancreatic_neuroendocrine_tumors_a_histochemical_and_immunohistochemical",
          "label": "Nash SV, Said JW. Gastroenteropancreatic neuroendocrine tumors: a histochemical and immunohistochemical study of epithelial (keratin proteins, carcinoembryonic antigen) and neuroendocrine (neuron-specific enolase, bombesin and chromogranin) markers in foregut, midgut, and hindgut tumors. Am J Clin Pathol. 1986;86(2):415-422.",
          "required": true,
          "type": "free_text"
        }
      ]
    }
  ]
}